Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
Francisco López-Jiménez(Mayo Clinic in Arizona), John Wilding(University of Liverpool), Emanuele Di Angelantonio(University of Cambridge), Fausto J. Pinto(University of Lisbon), Marie Chan Sun(University of Mauritius), Ada Cuevas(Finis Terrae University), Harold Bays(Louisville Metabolic and Atherosclerosis Research Center), Wael Almahmeed(Abu Dhabi Health Services), Gary Wittert(South Australian Health and Medical Research Institute), Naveed Sattar(University of Glasgow), Carel W. le Roux(University College Dublin)
Cited by 334
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k